PVSRIPO is an interferon-resistant, immunotherapeutic oncolytic virus
Publication
, Conference
Walton, R; Brown, M; Holl, E; Boczkowski, D; Chandramohan, V; Nair, S; Gromeier, M
Published in: JOURNAL FOR IMMUNOTHERAPY OF CANCER
November 7, 2017
Duke Scholars
Published In
JOURNAL FOR IMMUNOTHERAPY OF CANCER
ISSN
2051-1426
Publication Date
November 7, 2017
Volume
5
Publisher
BMC
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Walton, R., Brown, M., Holl, E., Boczkowski, D., Chandramohan, V., Nair, S., & Gromeier, M. (2017). PVSRIPO is an interferon-resistant, immunotherapeutic oncolytic virus. In JOURNAL FOR IMMUNOTHERAPY OF CANCER (Vol. 5). BMC.
Walton, Ross, Michael Brown, Eda Holl, David Boczkowski, Vidya Chandramohan, Smita Nair, and Matthias Gromeier. “PVSRIPO is an interferon-resistant, immunotherapeutic oncolytic virus.” In JOURNAL FOR IMMUNOTHERAPY OF CANCER, Vol. 5. BMC, 2017.
Walton R, Brown M, Holl E, Boczkowski D, Chandramohan V, Nair S, et al. PVSRIPO is an interferon-resistant, immunotherapeutic oncolytic virus. In: JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC; 2017.
Walton, Ross, et al. “PVSRIPO is an interferon-resistant, immunotherapeutic oncolytic virus.” JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 5, BMC, 2017.
Walton R, Brown M, Holl E, Boczkowski D, Chandramohan V, Nair S, Gromeier M. PVSRIPO is an interferon-resistant, immunotherapeutic oncolytic virus. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC; 2017.
Published In
JOURNAL FOR IMMUNOTHERAPY OF CANCER
ISSN
2051-1426
Publication Date
November 7, 2017
Volume
5
Publisher
BMC
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology